Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningiomas
NCT04305470Phase 3Completed
- Sponsor
- NX Development Corp.
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of 5-aminolevulinic acid in meningioma, sponsored by NX Development Corp. Primary endpoint: Percentage of Participants Where Gleolan-induced PpIX Fluorescence Status is Consistent With Histology at Day 1. Started Oct 2020; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT04305470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305470.